Abstract:Background: Acute lung injury (ALI) is a continuum of lung changes caused by multiple lung injuries, characterized by a syndrome of uncontrolled systemic inflammation that often leads to significant morbidity and death. Anti-inflammatory is one of its treatment methods, but there is no safe and available drug therapy. Syringic acid (SA) is a natural organic compound commonly found in a variety of plants, especially in certain woody plants and fruits. In modern pharmacological studies, SA has anti-inflammatory effects and therefore may be a potentially safe and available compound for the treatment of acute lung injury. Purpose: This study attempts to reveal the protective mechanism of SA against ALI by affecting the polarization of macrophages and the activation of NF-κB signaling pathway. Trying to find a safer and more effective drug therapy for clinical use. Methods: We constructed the ALI model using C57BL/6 mice by intratracheal instillation of LPS (10 mg/kg). Histological analysis was performed with hematoxylin and eosin (H&E). The wet-dry ratio of the whole lung was measured to evaluate pulmonary edema. The effect of SA on macrophage M1-type was detected by flow cytometry. BCA protein quantification method was used to determine the total protein concentration in bronchoalveolar lavage fluid (BALF). The levels of Interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α in BALF were determined by the ELISA kits, and RT-qPCR was used to detect the expression levels of IL-6, IL-1β and TNF-α mRNA of lung tissue. Western blot was used to detect the expression levels of iNOS and COX-2 and the phosphorylation of p65 and IκBα in the NF-κB pathway in lung tissue. In vitro experiments were conducted with RAW267.4 cell inflammation model induced by 100 ng/ml LPS and A549 cell inflammation model induced by 10 μg/ml LPS. The effects of SA on M1-type and M2-type macrophages of RAW267.4 macrophages induced by LPS were detected by flow cytometry. The toxicity of compound SA to A549 cells was detected by MTT method which to determine the safe dose of SA. The expressions of COX-2 and the phosphorylation of p65 and IκBα protein in NF-κB pathway were detected by Western blot. Results: We found that the pre-treatment of SA significantly reduced the degree of lung injury, and the infiltration of neutrophils in the lung interstitium and alveolar space of the lung. The formation of transparent membrane in lung tissue and thickening of alveolar septum were significantly reduced compared with the model group, and the wet-dry ratio of the lung was also reduced. ELISA and RT-qPCR results showed that SA could significantly inhibit the production of IL-6, IL-1β, TNF-α. At the same time, SA could significantly inhibit the expression of iNOS and COX-2 proteins, and could inhibit the phosphorylation of p65 and IκBα proteins. in a dose-dependent manner. In vitro experiments, we found that flow cytometry showed that SA could significantly inhibit the polarization of macrophages from M0 type macrophages to M1-type macrophages, while SA could promote the polarization of M1-type macrophages to M2-type macrophages. The results of MTT assay showed that SA had no obvious cytotoxicity to A549 cells when the concentration was not higher than 80 μM, while LPS could promote the proliferation of A549 cells. In the study of anti-inflammatory effect, SA can significantly inhibit the expression of COX-2 and the phosphorylation of p65 and IκBα proteins in LPS-induced A549 cells. Conclusion: SA has possessed a crucial anti-ALI role in LPS-induced mice. The mechanism was elucidated, suggesting that the inhibition of macrophage polarization to M1-type and the promotion of macrophage polarization to M2-type, as well as the inhibition of NF-κB pathway by SA may be the reasons for its anti-ALI. This finding provides important molecular evidence for the further application of SA in the clinical treatment of ALI.

Therapeutic Inhibition of CXC Chemokine Receptor 2 by SB225002 Attenuates LPS-induced Acute Lung Injury in Mice

Effect of adenylate cyclase antagonists andagonist in acute lung injury induced by lipopolysaccharide

Penehyclidine Hydrochloride Attenuates LPS-induced Acute Lung Injury Involvement of NF-kappaB Pathway.

Roles of CCR2b and CCR1 Antagonist RS504393 in LPS-induced Acute Lung Injury

A CRTH2 Antagonist, CT-133, Suppresses NF-κB Signalling to Relieve Lipopolysaccharide-Induced Acute Lung Injury.

Roles of CC chemokine receptors (CCRs) on lipopolysaccharide-induced acute lung injury.

[Protective Effect of Synthetic Salidroside on Acute Lung Injury in Rats].

Effects of ambroxol on nuclear factor-kappa B signaling transduction in lipopolysaccaride-induced acute lung injury in rats

Sphingosine-1-phosphate Receptor-2 Attenuates Lipopolysaccharide-Induced Acute Lung Injury

Inhibition of Pyk2 Blocks Lung Inflammation and Injury in a Mouse Model of Acute Lung Injury

Stlr4/smd-2 Complex Alleviates LPS-induced Acute Lung Injury by Inhibiting Pro-Inflammatory Cytokines and Chemokine CXCL1 Expression

Syringic acid attenuates acute lung injury by modulating macrophage polarization in LPS-induced mice

SB203580 Protects Against Inflammatory Response and Lung Injury in a Mouse Model of Lipopolysaccharide‑induced Acute Lung Injury.

Angiotensin II type 2 receptor agonist attenuates LPS-induced acute lung injury through modulating THP-1-derived macrophage reprogramming

CXCR3 May Help Regulate the Inflammatory Response in Acute Lung Injury Via a Pathway Modulated by IL-10 Secreted by CD8 + CD122+ Regulatory T Cells.

[BRL-44408 Maleate, the Antagonist of Α2a-Adrenoceptor, Attenuates Endogenous Lipopolysacchride-Induced Acute Lung Injury Through Inhibiting the Mitogen-Activated Protein Kinase Kinase/extracellular Regulated Protein Kinases Signaling Pathway in Mice].

Biphasic effects of selective inhibition of transforming growth factor beta1 activin receptor-like kinase on LPS-induced lung injury

Salvianolic Acid A Protects against Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting Neutrophil NETosis

Andrographolide Derivative AL-1 Ameliorates LPS-induced Acute Lung Injury by Inhibiting NLRP3 Inflammasome and Lung Permeability

Inhibition of SHP2 by the Small Molecule Drug SHP099 Prevents Lipopolysaccharide-Induced Acute Lung Injury in Mice

The Myosin II Inhibitor, Blebbistatin, Ameliorates Pulmonary Endothelial Barrier Dysfunction in Acute Lung Injury Induced by LPS Via NMMHC IIA/Wnt5a/β-catenin Pathway